Emilia Caselli

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 8

Top Topics

Molecular Dynamics Simulations

Diffusion Weighted

Acinetobacter Baumannii

Top Venues

Antibiotics (Basel, Switzerland)

Antimicrobial agents and chemotherapy

ACS infectious diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Maria Luisa Introvigne, Trevor J Beardsley, Micah C Fernando, David A Leonard, Bradley J Wallar, Susan D Rudin, Magdalena A Taracila, Philip N Rather, Jennifer M Colquhoun, Shaina Song, Francesco Fini, Kristine M Hujer, Andrea M Hujer, Fabio Prati, Rachel A Powers, Robert A Bonomo, Emilia Caselli
Sulfonamidoboronic Acids as "Cross-Class" Inhibitors of an Expanded-Spectrum Class C Cephalosporinase, ADC-33, and a Class D Carbapenemase, OXA-24/40: Strategic Compound Design to Combat Resistance in Acinetobacter baumannii . Antibiotics (Basel, Switzerland) 12 (4) (2023)
Andrew R Mack, Vijay Kumar, Magdalena A Taracila, María Fernanda Mojica, Margaret O'Shea, William Schinabeck, Galen Silver, Andrea M Hujer, Krisztina M Papp-Wallace, Shuang Chen, Shozeb M Haider, Emilia Caselli, Fabio Prati, Focco van den Akker, Robert A Bonomo
Natural protein engineering in the Ω-loop: the role of Y221 in ceftazidime and ceftolozane resistance in Pseudomonas -derived cephalosporinase. Antimicrobial agents and chemotherapy (2023)
Maria Luisa Introvigne, Trevor J Beardsley, Micah C Fernando, David A Leonard, Bradley J Wallar, Susan D Rudin, Magdalena A Taracila, Philip N Rather, Jennifer M Colquhoun, Shaina Song, Francesco Fini, Kristine M Hujer, Andrea M Hujer, Fabio Prati, Rachel A Powers, Robert A Bonomo, Emilia Caselli
Sulfonamidoboronic Acids as "Cross-Class" Inhibitors of an Expanded-Spectrum Class C Cephalosporinase, ADC-33, and a Class D Carbapenemase, OXA-24/40: Strategic Compound Design to Combat Resistance in Acinetobacter baumannii . Antibiotics (Basel, Switzerland) 12 (4) (2023)
Rachel A Powers, Cynthia M June, Micah C Fernando, Erin R Fish, Olivia L Maurer, Rachelle M Baumann, Trevor J Beardsley, Magdalena A Taracila, Susan D Rudin, Kristine M Hujer, Andrea M Hujer, Nicolo Santi, Valentina Villamil, Maria Luisa Introvigne, Fabio Prati, Emilia Caselli, Robert A Bonomo, Bradley J Wallar
Synthesis of a Novel Boronic Acid Transition State Inhibitor, MB076: A Heterocyclic Triazole Effectively Inhibits Acinetobacter -Derived Cephalosporinase Variants with an Expanded-Substrate Spectrum. Journal of medicinal chemistry (2023)
Peggy Lu, Francesco Alletto, Bosul Lee, Elizabeth Burk, Jasmine Martinez, Fabio Prati, Emilia Caselli, Brad Spellberg, Brian M Luna
Defining the minimum inhibitory concentration of 22 rifamycins in iron limited, physiologic medium against Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae clinical isolates. PloS one 18 (6) (2023)
Francesco Fini, Alessandro Zanni, Maria Luisa Introvigne, Mattia Stucchi, Emilia Caselli, Fabio Prati
Straightforward synthesis of chiral non-racemic α-boryl isocyanides. Organic & biomolecular chemistry 19 (30) (2022)
Emilia Caselli, Francesco Fini, Maria Luisa Introvigne, Mattia Stucchi, Magdalena A Taracila, Erin R Fish, Kali A Smolen, Philip N Rather, Rachel A Powers, Bradley J Wallar, Robert A Bonomo, Fabio Prati
1,2,3-Triazolylmethaneboronate: A Structure Activity Relationship Study of a Class of β-Lactamase Inhibitors against Acinetobacter baumannii Cephalosporinase. ACS infectious diseases 6 (7) (2020)
Scott T Lefurgy, Emilia Caselli, Magdalena A Taracila, Vladimir N Malashkevich, Beena Biju, Krisztina M Papp-Wallace, Jeffrey B Bonanno, Fabio Prati, Steven C Almo, Robert A Bonomo
Structures of FOX-4 Cephamycinase in Complex with Transition-State Analog Inhibitors. Biomolecules 10 (5) (2020)